Patent eLigibiLity iSSUeS in ReCent yeaRS
نویسنده
چکیده
The patent laws are in the U.S. Constitution dating back from 1790 to 1793 to promote, as articulated by one of the framers, Thomas Jefferson, and protect ‘any new and useful art, machine, manufacture, or composition of matter, or any new or useful improvement thereof ’. Although the U.S. Congress in 1952 replaced the word ‘art’ with the word ‘process’, the Congress, as well as the courts, have strived to retain the basic philosophy of the Constitutional mandate that ‘ingenuity should receive a liberal encouragement’. In accordance with such constitutional mandate, and to follow the spirit of the mandate, the U.S. Supreme Court in 1980 boldly declared in the case Diamond v. Chakrabarty (447 U.S. 303, 1980) that ‘anything under the sun that is made by man’ is patent eligible under the patent laws as long as it meets the statutory requirement of novelty (35 USC section 102), non-obviousness (section 103), detailed description for enablement (section 112) and utility (section 101/112). It is noteworthy that the framers of the Constitution not only put such language in the Constitution but to emphasize the spirit of such mandate, when the first US patent was granted to Samuel Hopkins on July 31, 1790 for 14 years, President George Washington and the Attorney General Edm. Randolph signed this issued patent followed by Secretary of State Thomas Jefferson who also signed and delivered the patent to Mr. Hopkins on the 4th of August, 1790. This was thus an exciting beginning of both the promotion of the inventive spirit, legal protection of such inventions for a period of time, and the economic development in the United States. This commentary deals with a patent eligibility issue decided by the US Supreme Court on June 13, 2013 in the case Association for Molecular Pathology, et al v. Myriad Genetics, Inc., et al (No. 12-398), where the Supreme Court held that a naturally-occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated.
منابع مشابه
Patent first, ask questions later: morality and biotechnology in patent law.
This Article explores the U.S. "patent first, ask questions later" approach to determining what subject matter should receive patent protection. Under this approach, the U.S. Patent and Trademark Office (USPTO or the Agency) issues patents on "anything under the sun made by man," and to the extent a patent's subject matter is sufficiently controversial, Congress acts retrospectively in assessin...
متن کاملتعارض اصل حمایت از اختراعات دارویی و حقوق بشر؛ تفسیر حقوقی ماده 27 موافقتنامه تریپس
Today, pharmaceutical patents constitute an important part of industrial production and investment corporations have shown interest in this issue which is willing to protect these patents for assurance of investment in this area. While progress in this field has human interests, but the unconditional protection of such patents is in conflict with the right to health as one of the fundamental hu...
متن کاملInterfacing of Science, Medicine and Law: The Stem Cell Patent Controversy in the United States and the European Union
The patent eligibility of stem cells-particularly those derived from human embryos-has long been under debate in both the scientific and legal communities. On the basis of moral grounds, the European Patent Office (EPO) has refrained from granting patents for stem cells obtained through the destruction of human embryos. On the contrary, the United States Patent and Trademark Office (USPTO) has ...
متن کاملAlice and ‘something more’: the drift towards European patent jurisprudence
On the face of it, the doctrinal lines of disagreement around ‘subject matter eligibility’ inUS law and ‘the invention requirement’, as it is known inEurope, could not be further apart.The US statute is silent as to what does not constitute patentable subject matter, while the European Patent Convention (EPC) takes a much more formal approach. Unpatentable subject matter is listed, categorized ...
متن کاملStanding on shaky ground: US patent-eligibility of isolated DNA and genetic diagnostics after AMP v USPTO – Part III
At first reading, the Federal Circuit’s decision in AMP v USPTO, summarized in Part I of this four-partite paper appears to favor the biotechnological and pharmaceutical industry. Its practical impact seems moderate because clever claim drafting helps to avoid most patent eligibility traps. Yet, the split decision also contains elusive reasoning by each of the three judges that provides excelle...
متن کامل